Meskacel™ HPMC K100 Pharma Grade API is a hydroxypropyl methylcellulose, pharmacopoeially designated hypromellose, supplied for tablet, capsule, granule, and oral/injectable dosage-form manufacture. The K100 designation denotes a nominal apparent viscosity of 100 mPa·s in 2.0% w/w aqueous solution at 20 °C, measured by capillary viscometer under USP <911> and Ph.Eur. 2.2.9. The material corresponds to substitution type 2208, with methoxyl content of 19.0–24.0% and hydroxypropoxyl content of 4.0–12.0% on the dried basis. Because the polymer is non-ionic, aqueous K100 solutions remain electrically indifferent over the pH range 3.0–11.0, but hydration behaviour is strongly temperature-dependent. The powder is supplied as a white to slightly off-white material with particle-size distribution, loss on drying, sulfated ash, and residual solvent content controlled on the certificate of analysis.

In dry-powder handling, particle-size distribution is matched to the intended unit operation. Fine grades with median particle size near 45 µm are used for direct blending and dry granulation; coarser grades near 180 µm reduce dust generation but hydrate more slowly in aqueous systems. Powder flow under gravity is moderate. Angle of repose can range from 35° to 45° depending on particle-size distribution and moisture content. High-speed rotary tablet presses typically require a glidant because K100 does not exhibit free-flowing behaviour sufficient for direct feeding without flow aid.

What Distinguishes K100 from Lower- or Higher-Viscosity Hypromellose Grades?

K100 occupies an intermediate position between low-viscosity hypromellose grades used for aqueous film coating and high-viscosity grades used for extended-release matrix systems. An E5 grade with nominal viscosity 5 mPa·s can be sprayed at higher solids but contributes limited gel strength. A K4M grade with nominal viscosity 4,000 mPa·s or a K15M grade with nominal viscosity 15,000 mPa·s produces a more rigid gel layer but requires lower solids during liquid preparation and slower hydration fronts. K100 remains pumpable at 3–6% w/w aqueous concentration in spray granulation while still providing sufficient wet-mass adhesion for granule formation. The following table summarises the comparative profile.

For hydrophilic matrix tablets, K100 forms a gel layer with intermediate firmness. At matrix polymer levels below 10% w/w, gel-layer integrity may be insufficient for low-solubility active pharmaceutical ingredients, and tablet erosion can dominate release. At 40% w/w, diffusion through the hydrated layer becomes the rate-limiting process. Dissolution characterisation should follow USP <711> apparatus 2 at 50 rpm. Testing in 0.1 M HCl for 2 h followed by phosphate buffer pH 6.8 is relevant because the K100 matrix is non-ionic but the drug substance may have pH-dependent solubility. K100 does not provide enteric protection and should not be substituted for hypromellose phthalate or methacrylic acid copolymers when gastric resistance is required.

In USP <711> apparatus 2 at 50 rpm, hydration occurs more rapidly than with K4M and less rapidly than with E5. This does not create enteric behaviour; release remains pH-independent across the physiological pH range, although drug solubility may vary. Published data for this specific grade in controlled-release matrices is limited to formulation-specific studies, so matrix polymer level, tablet porosity, and hydrodynamic conditions should be verified for each formulation.

Compendial Specification Profile and Certificate-of-Analysis Parameters

Routine lot release includes identity, viscosity, methoxyl and hydroxypropoxyl substitution, loss on drying, sulfated ash, and microbial enumeration. The lot certificate of analysis is the controlling document for exact acceptance ranges. Table 2 lists pharmacopoeial anchors commonly applied during batch disposition.

Batch-to-batch viscosity variance within the compendial range can affect downstream processing. A lot at the upper end of the acceptance range may require reduced solids in spray granulation or additional water in wet massing. High-shear granulation endpoints should therefore be controlled by impeller torque rather than fixed-time addition. The grade designation alone does not confer route-specific regulatory approval; injectable use requires additional controls beyond oral solid-dose requirements.

When Aqueous Granulation and Direct Compression Share a Binder Grade

Direct compression with K100 at 3–5% w/w of the core mass functions as a dry binder. The material is hygroscopic; exposure above 60% RH increases moisture content and may reduce flow. Preconditioning in a bin at 25 °C and 35% RH for 24 h is common before tableting for moisture-sensitive actives. In high-shear wet granulation, a vertical granulator with impeller tip speed 3–6 m/s and chopper speed 1,500 rpm is used; endpoint is controlled by impeller torque. Aqueous K100 solution at 3–6% w/w is preferred over dry addition because it distributes binder more uniformly at low water addition levels. At binder levels above 5% w/w, tablet hardness increases but disintegration may be delayed; croscarmellose sodium at 2–3% w/w is commonly added to offset gel formation on wetting.

For fluid-bed granulation, K100 solution at 4–6% w/w is sprayed with inlet air temperature 50–70 °C, product temperature 28–38 °C, and target wet-mass moisture 12–16%. Spray-dried granules containing K100 can be compressed directly after milling; fines below 75 µm should be kept below 15% of total mass to reduce capping tendency. Hard capsule filling on dosator machines requires granules with Hausner ratio 1.20–1.40 and Carr index 15–25%; over-granulated K100 can produce hard granules that resist tamping and increase fill-weight variation.

For oral granules and reconstitutable powders, K100 at 1–2% w/w in the final reconstituted vehicle increases low-shear viscosity and reduces sedimentation of dispersed active pharmaceutical ingredients. Sedimentation volume should be measured after 24 h in water at 25 °C. Published data for this specific grade in oral suspension formulations is limited, so formulation-specific settling studies are required.

Controlling Hydration and Gel Strength in Aqueous Systems

Hydration of K100 is temperature-dependent. The polymer disperses in hot water without hydrating and develops viscosity only when the temperature is reduced below 10 °C. A standard manufacturing sequence disperses the powder in one-third of the required Purified Water at 70–80 °C, then adds the remaining water as chilled water under low-shear stirring. Full viscosity development may require 60–120 min. Solutions above 4% w/w exhibit pseudoplastic flow; single-spindle viscosity data are insufficient for batch comparison. In coating operations, vacuum deaeration at −0.08 MPa to −0.09 MPa for 15–30 min reduces film defects from entrained air.

Thermal gelation for hypromellose type 2208 is commonly observed between 60 °C and 80 °C in water, depending on concentration and heating rate. This behaviour imposes an upper limit on exhaust air temperature during aqueous subcoating and spray granulation. If the droplet film reaches the gelation temperature before spreading, orange-peel surface defects can appear on tablet cores.

Aqueous film coating with K100 is feasible at low solids, typically 4–8% w/w. Using a side-vented pan with spray-gun atomising air pressure 1.5–2.0 bar, tablet bed temperature 38–42 °C, and exhaust air temperature below 60 °C, a continuous film can be formed without premature gelling. K100 films provide moderate moisture protection and are not a substitute for non-porous enteric films.

Injectable and Ophthalmic Processing Boundaries Are Not Defined by Viscosity Alone

Hypromellose K100 has a history of use as a viscoelastic agent and ophthalmic lubricant. The injectable-grade presentation requires bacterial endotoxin testing by Ph.Eur. 2.6.14 and microbial enumeration by Ph.Eur. 2.6.12 and Ph.Eur. 2.6.13. Solutions intended for surgical or ophthalmic use should be prepared in Water for Injection and filtered through a 0.22 µm sterilizing-grade membrane. Filtration of K100 at 2% w/w is performed at 35–45 °C to reduce viscosity; cold filtration may exceed differential pressure limits of the membrane. Terminal steam sterilisation at 121 °C for 15 min may reduce molecular weight and shift viscosity, so pre- and post-sterilisation viscosity must be measured under USP <911>. If the material is used in a parenteral depot, release kinetics are formulation-specific and must be validated; published data for this specific grade in such systems is limited.

The material is not supplied sterile. Terminal sterilisation or aseptic filtration is required for injectable manufacture. For aseptic filtration, the solution should be prefiltered through a clarifying membrane before sterilizing-grade filtration. Viscosity increases sharply as concentration exceeds 2% w/w, and filtration time through a 0.22 µm membrane becomes a processing bottleneck at low temperature. Concentration and temperature must therefore be selected before scale-up.

K100 is incompatible with strong oxidising agents, including concentrated peroxides and hypochlorite-based sanitising solutions, which can cause chain scission and viscosity loss. The material is hygroscopic and should be stored in closed containers below 25 °C and 35% RH. It is not an enteric polymer, and it is not a direct substitute for crosslinked hyaluronic acid in intra-articular viscosupplements. Opened containers should be resealed immediately after use.